Inclusion Criteria:

• Histologically proven epithelial carcinoma of the ovary or of the fallopian tube or extraovarian papillary serous carcinoma with extent to the ovary
• International Federation of Gynecology and Obstetrics (FIGO) stage IIB-IV, regardless of measurable or non-measurable disease
• No prior chemo- or radiotherapy

• Adequate hematologic, renal and hepatic function:

  • ANC ≥ 1.5 x 10^9/L,
  • Platelet counts ≥ 100 x 10^9/L,
  • Total bilirubin ≤ 1.5 x upper normal limit,
  • Alkaline Phosphatase ≤ 3 x upper normal limit,
  • Serum creatinine ≤ 1.25 upper normal limit,
  • Estimated GFR ≥ 60 ml/min
• Performance status 0-2 (ECOG)
• Life expectancy must be greater than 12 weeks

Exclusion Criteria:

• Non-epithelial tumors or mixed epithelial/non-epithelial tumors (e.g. mixed Mullerian tumors) or tumors of low malignant potential (borderline tumors)
• Prior treatment with chemo- or radiotherapy
• Administration of other simultaneous chemotherapeutic drugs or hormonal therapy or simultaneous radiotherapy during the study treatment period or planned whole abdominal radiotherapy
• History of congestive heart failure
• Symptomatic brain metastasis
• Complete bowel obstruction
• Dementia
• Active infection or other serious underlying medical condition
• Pre-existing motor or sensory neurologic pathology